false
0001971532
0001971532
2025-10-08
2025-10-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 8, 2025
TELOMIR
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in its Charter)
| Florida |
|
001-41952 |
|
87-2606031 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
100
SE 2nd St, Suite
2000, #1009
Miami,
Florida, 33131
(Address
of Principal Executive Offices)
Registrant’s
telephone number, including area code: (786) 396-6723
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| |
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
|
| |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
|
| |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
|
| |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
| Common
Stock, no par value |
|
TELO |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
8.01 Other Events
Telomir
Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells
New
findings show Telomir-1 shuts down cellular energy pathways and mitochondrial function in aggressive breast cancer cells, leading to
cell death through iron-dependent regulation.
Telomir
Pharmaceuticals, Inc. (NASDAQ: TELO), a preclinical-stage biotechnology company developing therapies that target epigenetic drivers
of cancer, aging, and age-related disease, announced new findings demonstrating that Telomir-1 significantly reduces the survival of
aggressive triple-negative breast cancer (TNBC) cells — a highly invasive form of breast cancer that lacks hormone and HER2 receptors,
offers limited treatment options, and carries one of the poorest survival rates among breast cancer subtypes.
In
laboratory studies using human triple-negative breast cancer cells, Telomir-1 produced a clear, concentration-dependent reduction in
cancer cell survival. As Telomir-1 concentrations increased, more cancer cells lost their ability to grow and survive. When iron was
added back to the system, the cells recovered, confirming that the compound’s activity is linked to the regulation of cellular
iron and energy balance.
The
iron dependency observed in this study is significant because aggressive cancer cells, such as those found in TNBC, are among the most
metabolically active of all breast cancer types. These cells depend on iron to support their rapid growth and survival, and iron metabolism
contributes directly to this aggressive behavior. By disrupting that iron-driven process, Telomir-1 appears to exploit a core metabolic
weakness unique to these tumors. This selectivity is important because normal cells manage iron differently and are less dependent on
it, suggesting that Telomir-1 may preferentially affect cancer cells while sparing healthy tissue.
Telomir-1
has previously been shown to reset abnormal DNA methylation patterns and restore balanced gene expression in models of cancer and age-related
disease. In TNBC, certain iron-dependent enzymes—known as Jumonji domain histone demethylases (KDMs), including KDM5A/B and KDM6B—are
thought to drive gene expression changes that make cancer cells more aggressive and resistant to therapy. The new findings suggest that
Telomir-1’s observed effects on energy regulation and iron balance may stem from its ability to influence these same epigenetic
mechanisms. Many aggressive cancers show methylation changes that activate pathways controlling iron use, oxidative stress, and energy
metabolism. By helping to restore normal epigenetic control, Telomir-1 may indirectly rebalance these pathways, offering new insight
into its broader mechanism of action.
The
Company plans to expand these studies to include additional cancer types, such as pancreatic and leukemia models, and to conduct further
animal studies in preparation for its Investigational New Drug (IND) submission.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
TELOMIR
PHARMACEUTICALS, INC. |
| |
|
| Dated:
October 8, 2025 |
By: |
/s/
Erez Aminov |
| |
Name:
|
Erez
Aminov |
| |
Title: |
Chief
Executive Officer |
